An enhanced capacity for de novo lipid synthesis is a metabolic feature of most cancer cells that distinguishes them from their cells of origin. However, the mechanisms through which oncogenes alter lipid metabolism are poorly understood. We find that expression of oncogenic PI3K (H1047R) or K-Ras (G12V) in breast epithelial cells is sufficient to induce de novo lipogenesis, and this occurs through the convergent activation of the mechanistic target of rapamycin complex 1 (mTORC1) downstream of these common oncogenes. Oncogenic stimulation of mTORC1 signaling in this isogenic setting or a panel of eight breast cancer cell lines leads to activation of the sterol regulatory element-binding proteins (SREBP1 and SREBP2) that are required for oncogene-induced lipid synthesis. The SREBPs are also required for the growth factor-independent growth and proliferation of oncogene-expressing cells. Finally, we find that elevated mTORC1 signaling is associated with increased mRNA and protein levels of canonical SREBP targets in primary human breast cancer samples. These data suggest that the mTORC1/SREBP pathway is a major mechanism through which common oncogenic signaling events induce de novo lipid synthesis to promote aberrant growth and proliferation of cancer cells.
INTRODUCTION
The genetic events underlying cancer development are accompanied by the induction of a metabolic program, distinct from most normal cells, that facilitates the uncontrolled growth of cancer cells. However, the key molecular connections between the most commonly activated oncogenic pathways in human cancers and this metabolic reprogramming are poorly defined. One longknown, but poorly understood, alteration in cellular metabolism frequently observed in cancer is the activation of de novo lipid synthesis, 1 a process that only minimally contributes to the lipid content of normal nonproliferating cells. Although normal cells generally rely on the uptake of lipids from the circulation, cancer cells often acquire the ability to make their own, which is believed to be required to meet an increase demand for membrane biogenesis during cell proliferation. 2, 3 The expression of genes encoding lipogenic enzymes, including acetyl-CoA carboxylase (ACACA), fatty acid synthase (FASN) and steroyl-CoA desaturase (SCD), has been found to be elevated in a variety of cancers. 2, 4, 5 In normal, lipid-producing tissues, such as the liver, these and most other enzymes involved in de novo sterol and fatty acid synthesis are induced by the sterol regulatory element (SRE) binding protein (SREBP) family of transcription factors, SREBP1 and 2. 6 The SREBPs are produced as inactive precursors that reside as transmembrane proteins in the endoplasmic reticulum. [7] [8] [9] [10] [11] When sterols or unsaturated fatty acids become depleted, the membrane-bound SREBP traffics to the Golgi, where it is sequentially cleaved by two site-specific proteases. The N-terminal fragment of SREBP, representing the active transcription factor (referred to as the mature form), is released and can enter the nucleus to activate target genes with SREs in their promoters. Through transcriptional activation of its lipogenic target genes, SREBP is able to induce the de novo synthesis of sterols, fatty acids and their neutral lipid derivatives.
In addition to its regulation by lipids, SREBP isoform processing and activation have been found to be stimulated by insulin and growth factor signaling through mechanistic target of rapamycin complex 1 (mTORC1). 12 Activation of mTORC1 signaling induces SREBP activation in cell culture models and in the liver, leading to the accumulation of mature processed SREBP, expression of SREBP target genes and increased de novo lipid synthesis. [13] [14] [15] [16] The molecular mechanism by which mTORC1 activates SREBP remains unknown but likely involves multiple direct downstream targets. Independent groups have shown that mTORC1 can promote SREBP processing through the mTORC1-regulated protein kinase S6K1 in various settings. 13, [17] [18] [19] [20] 4E-BP1, an inhibitor of capdependent translation that is blocked by mTORC1 signaling, has also been implicated in the regulation of SREBP downstream of mTORC1. 18, 21 In addition, phosphorylation of the phosphatidic acid phosphatase Lipin1 by mTORC1 has been shown to promote accumulation of mature SREBP in the nucleus through an unknown mechanism. 22 An important feature of mTORC1 signaling that influences studies on its regulation of SREBP is that the downstream targets of mTORC1 are differentially sensitive to mTOR inhibitors. S6K1 phosphorylation and activation is completely inhibited by rapamycin, whereas 4E-BP1 and Lipin1 phosphorylation and inhibition are only partially sensitive to rapamycin. [22] [23] [24] As such, it is useful to use both rapamycin, an allosteric inhibitor of mTORC1, and mTOR kinase inhibitors, which completely inhibit both mTORC1 and mTORC2, in such studies.
In normal cells and tissues, mTORC1 activity is tightly controlled by growth factors through the convergence of multiple upstream signaling pathways on a protein complex comprising tuberous sclerosis complex (TSC) tumor suppressors, TSC1 and TSC2, and the TBC1D7 protein (the TSC complex). 25, 26 The TSC complex acts as a GTPase-activating protein (GAP) for Rheb, a Ras-related small G protein that potently activates mTORC1 when it is GTP bound. 27 Although loss-of-function mutations affecting the TSC complex lead to growth factor-independent activation of mTORC1 and are the genetic cause of the tumor syndromes TSC and lymphangioleiomyomatosis, 28 mutations in the complex components are more rare in sporadic cancers. Nonetheless, aberrant activation of mTORC1 is a frequent event in human cancers, across nearly all lineages. 29 Two of the most commonly activated pathways in cancer, the phosphatidylinositide 3-kinase (PI3K)/Akt and the Ras/extracellular signal-regulated kinase (Erk) pathways, converge on the TSC complex to activate mTORC1. [30] [31] [32] [33] [34] Here, we find that expression of oncogenic PI3K or K-Ras in normal cells induces de novo lipogenesis and that inhibition of mTORC1 or depletion of the SREBPs blocks this induction. We also find that this is a primary mechanism driving lipid synthesis in a panel of genetically-defined breast cancer lines. We find that depletion of the SREBPs hinders the viability and growth of cells with oncogenic activation of mTORC1 signaling. Lastly, we show an association between mTORC1 activation and expression of lipogenic targets of SREBP in primary human breast cancer samples. These findings identify the mTORC1/SREBP pathway as a major molecular link between oncogenic signaling events and the common increase in de novo lipid synthesis observed in human cancers.
RESULTS
Oncogenic PI3K and K-Ras are sufficient to induce de novo lipid synthesis and do so in an mTORC1-dependent manner As both the PI3K and Ras pathways are frequently activated in cancer and converge to activate mTORC1 (Figure 1a) , we asked whether activating mutants commonly found in human cancer (PIK3CA H1047R and K-Ras G12V ) were sufficient to stimulate lipogenesis. We generated an isogenic set of cell lines stably expressing either empty vector or one of these two oncogenic mutants in MCF10a cells, a nontransformed human breast epithelium cell line. The oncogene-expressing cells exhibited growth factorindependent activation of mTORC1, as detected by phosphorylation of its downstream targets, S6K1 and 4E-BP1, and the S6K target ribosomal S6 that were sensitive to rapamycin and the mTOR kinase inhibitor Torin1 (Figure 1b) . Consistent with these oncogenes activating mTORC1 primarily through distinct pathways, the PIK3CA H1047R cells displayed activated Akt but not Erk, whereas the K-Ras G12V cells had activated Erk with minimal activation of Akt. To measure specific effects on de novo lipid synthesis, cells were labeled with 14 C-acetate in order to avoid established effects of these oncogenes on glucose uptake. Importantly, both oncogenic PI3K and K-Ras stimulated an increase in the incorporation of acetate into lipid (Figure 1c) . Rapamycin significantly reduced this oncogene-induced lipogenesis, and treatment with two structurally distinct mTOR kinase inhibitors, PP242 (ref. 23) or Torin1, 24 led to a further reduction. To determine whether the effects of mTOR inhibitors on the induction of lipid synthesis by oncogenic PI3K and K-Ras were through inhibition of mTORC1 or mTORC2 (Figure 1a) , small interfering RNAs (siRNAs) targeting either mTORC1, through Raptor knockdown, or mTORC2, through Rictor knockdown, were introduced into these cells (Figure 1d ). In both oncogeneexpressing lines, Raptor knockdown decreased S6K1 phosphorylation. Rictor knockdown had the strongest effect on S6K1 phosphorylation in the PIK3CA H1047R cells, where the mTORC2 target Akt lies upstream of mTORC1. Importantly, de novo lipogenesis in the oncogene-expressing cells mirrored effects of these siRNAs on mTORC1 signaling, with Raptor knockdown inhibiting in both lines and Rictor knockdown having more pronounced effects in the PIK3CA H1047R cells (Figure 1e ). Therefore, oncogenic PI3K and K-Ras are sufficient to stimulate de novo lipid synthesis and do so through the common downstream activation of mTORC1.
Activation of SREBP downstream of mTORC1 is required for oncogene-induced lipid synthesis Given that mTORC1 has been found previously to stimulate de novo lipid synthesis through activation of the SREBP transcription factors in other settings, 13, 14 we assessed the effects of oncogenic PI3K and K-Ras on SREBP isoforms and canonical gene targets. Following cellular fractionation to detect the cytosolic, inactive precursor (P) and nuclear, active mature (M) forms of SREBP1 and 2, we found that levels of the SREBP1 precursor were modestly elevated in the oncogene-expressing lines, whereas the SREBP2 precursor was increased only in the oncogenic K-Ras cells (Figure 2a ). These increases matched closely with differential changes in the transcript levels of the genes encoding these proteins, SREBF1 and SREBF2 (Supplementary Figure S1a) . Consistent with previous findings suggesting that mTORC1 signaling promotes the processing of SREBP, 13, 20 the nuclear mature forms of both SREBP1 and 2 were elevated in the oncogene-expressing cells, and treatment with either rapamycin or Torin1 blocked this increase (Figure 2a) . The oncogenemediated activation of SREBP was reflected in elevated transcript (Figure 2b and S1a) and protein ( Figure 2a ) levels of three canonical SREBP targets, ACC1, FASN and SCD. Although the transcript levels of ACC1, FASN and SCD were all sensitive to mTORC1 inhibitors, only SCD was decreased at the protein level following overnight treatment, reflecting the long-lived nature of the ACC1 and FASN proteins. 35, 36 To determine whether the oncogene-induced increase in expression of lipogenic genes and stimulation of de novo lipid synthesis were through this mTORC1-dependent activation of SREBP isoforms, we used siRNAs to knock down SREBP1, SREBP2 or both. Consistent with redundant regulation of lipogenic gene targets by SREBP1 and 2, the double knockdown resulted in the strongest decrease in FASN and SCD protein ( Figure 2c ) and transcript levels ( Figure 2d ). Whereas the transcript levels of ACC1 were affected by SREBP knockdown, especially in the PIK3CA H1047R cells (Supplementary Figure S1b) , ACC1 protein levels were largely unaffected ( Figure 2c ). As observed in previous studies, 13, 37, 38 we found that SREBP2 knockdown, with siRNA sequences that do not directly target SREBP1, decreases SREBF1 transcript levels (Supplementary Figure S1b) , and this is also reflected in SREBP1 protein levels ( Figure 2c ). This cross-regulation likely reflects the presence of functional SREs in the SREBF1 gene promoter. 39 Importantly, as with mTORC1 inhibitors, oncogene-induced de novo lipogenesis was eliminated with siRNA-mediated knockdown of SREBP isoforms, with SREBP2 playing the dominant role in these cells (Figure 2e ).
Given that treatment with mTOR inhibitors for 16 h is sufficient to block oncogene-driven lipogenesis (Figure 1c ), but only SCD protein levels, not ACC1 or FASN, are decreased in this time frame (Figure 2a ), we determined whether inhibition of SCD could explain these inhibitory effects on lipogenesis. Indeed, siRNAmediated knockdown of SCD significantly reduced de novo lipogenesis, with a more pronounced effect in the PI3K H1047R cells, where the decrease mimicked SREBP1/2 knockdown ( Figures  2f and g ). Therefore, oncogenic PI3K and K-Ras can stimulate lipogenesis through the mTORC1-mediated activation of SREBP and its subsequent induction of SCD, the enzyme responsible for generating the monounsaturated fatty acids (MUFAs) prevalent in membrane phospholipids. mTORC1 and SREBP drive de novo lipid synthesis in breast cancer cells To determine whether mTORC1 signaling also promotes de novo lipid synthesis in the more complex genetic setting of cancer cells, we profiled a panel of eight genetically defined breast cancer cell lines of luminal and basal subtype that, among other mutations, have oncogenic activation of the PI3K or Ras signaling pathways (Table 1) . Consistent with the presence of these mutations leading to activation of the upstream pathways, all eight cell lines displayed growth factor-independent activation of mTORC1 signaling that was sensitive to rapamycin, PP242 or Torin1 (Figure 3a ). De novo lipogenesis was also constitutively active in these cells, and was significantly reduced by rapamycin in all cases, with mTOR kinase inhibitors leading to a further reduction in some lines (Figure 3a) . Inhibition of mTOR decreased the transcript levels of SREBF1, SREBF2, FASN and SCD in these lines ( Figure 3b and Supplementary Figure S2a) . Similar to the oncogene-expressing MCF10a cells, mTOR inhibitors had little effect on levels of SREBP precursors, but the mature forms of both SREBP1 and 2 were reduced by rapamycin and Torin1 in three representative lines from this panel ( Figure 3c ). As a control, we confirmed that the SREBP precursor and mature forms detected by these antibodies are reduced by siRNA-mediated knockdown of SREBP1 and 2 in these cells (Supplementary Figure S2b) . SCD protein levels were also reduced by mTOR inhibitors (Figure 3c ), whereas a substantial decrease in FASN levels were not observed until 96 h of treatment (Supplementary Figure S2c) , despite effects on its transcript levels at 18 h (Figure 3b) .
To determine the role of SREBP in the induction of lipogenesis in breast cancer cells, SREBP1, SREBP2 or both were knocked down using siRNAs in these three lines that we confirmed by measuring SREBF1, SREBF2, and SCD transcript levels (Supplementary Figure  S3) . Depletion of SREBP2 alone or in combination with SREBP1 attenuated the ability of these cells to synthesize lipids de novo (Figure 3d ). Therefore, aberrant mTORC1 signaling and its activation of SREBP isoforms underlie the lipogenic property of heterogeneous breast cancer cell lines.
The SREBPs support oncogene-induced cell proliferation and growth We next determined the importance of downstream activation of SREBP on the growth properties of breast cancer cells with activated mTORC1. The proliferation of MDA-MB-468, MDA-MB-453 and Hs578T grown in full serum was significantly reduced by combined knockdown of SREBP1 and 2, with the Hs578T cells being equally sensitive to SREBP2 knockdown alone (Supplementary Figure S4) . To determine the influence of exogenous lipids on these responses, proliferation was also measured in lipid-depleted serum. Although the overall responses to SREBP isoform knockdown were similar, reducing serum lipids greatly sensitized the MDA-MB-468 cells to the knockdown of SREBP2 (Figure 4a ). Exogenous expression of mouse SREBP2, which is resistant to the siRNAs targeting human SREBP2 and thereby restores FASN and SCD expression, rescued the inhibitory effects of SREBP2 knockdown on the proliferation of these cells ( Figure 4b ). As further confirmation of the specificity of these effects, four different shRNA sequences targeting SREBP2 were tested. The inhibition of proliferation with these shRNAs closely matched the degree of decrease in FASN and SCD protein levels elicited by the individual shRNAs (Figure 4c ). The knockdown of SREBP isoforms also led to a reduction in cell size, with the double knockdown having the strongest effect in all three cell lines tested (Figure 4d ). The differential effects of SREBP1 and SREBP2 depletion on the proliferation and growth of these cell lines were also observed for measurements of cell death, with the double knockdown most strongly decreasing viability (Figure 4e ). Therefore, SREBP plays a key role in supporting cell growth, proliferation and survival in these breast cancer cells.
To better define the cellular role of SREBP as a downstream effector of oncogenic signaling pathways, we compared the PIK3CA H1047R -and K-Ras G12V -expressing MCF10a cells with the isogenic vector-expressing cells. When grown in full serum, the proliferation rate of the vector control cells was comparable to the oncogene-expressing cells (Figure 5a) , and knocking down SREBP isoforms, particularly SREBP2, only modestly reduced proliferation in the oncogene-expressing lines (Figure 5b ). To better distinguish between the control cells, which exhibit growth factor-dependent mTORC1 activation, and the oncogene-expressing lines, with constitutive mTORC1 activation (Figure 1b) , proliferation was also measured in low serum and growth factor conditions, where both the PI3K and K-Ras cells exhibit a proliferation advantage over the controls (Figure 5c ). Under these conditions, SREBP2 knockdown arrested the proliferation of both oncogene-expressing lines, an effect enhanced when combined with SREBP1 knockdown (Figure 5d ). The oncogene-expressing cells also exhibited an increase in cell size relative to the control cells (Figure 5e ), and their size was significantly reduced upon knockdown of SREBP2 alone or in combination with SREBP1 (Figure 5f ). Collectively, these findings reveal a requirement for SREBP in the aberrant, growth factor-independent growth and proliferation of oncogeneexpressing cells.
Association of mTORC1 activation with the expression of SREBP targets in human breast cancer To determine whether the mTORC1/SREBP pathway is activated in human breast cancers, we analyzed the coupled gene expression and reverse-phase protein array data from the breast invasive carcinoma data set of The Cancer Genome Atlas (TCGA). [40] [41] [42] Using phosphorylation of ribosomal S6 (P-S6) as an indication of mTORC1 activation, the expression of canonical SREBP targets in cells with low and high mTORC1 signaling was compared. When compared with tumors with low P-S6 (n = 116), those with high P-S6 (n = 112) displayed increased expression of the SREBP target genes FASN, SCD, LDLR and MVK (Figure 6a) . To further assess a connection between mTORC1 activation and increased protein levels of SREBP targets, we used arrays of protein extracts from primary breast cancer samples comprising matched pairs of tumor and adjacent normal breast tissue from each patient (n = 40), comparing P-S6 levels with that of FASN and SCD. To validate the antibodies for this assay, we used dot blots of MDA-MB-468 cell lysates and confirmed the decreased signal in lysates from Torin1-treated cells (Supplementary Figure S5) . Examples of the array data with triplicate spots of normal and tumor tissue from each of six patients are shown in Figure 6b . An association between the fold change in P-S6 levels in the tumor samples relative to their matched normal tissue and the fold change in FASN and, especially, SCD protein levels was evident in this analysis (Figure 6c ). FASN and SCD protein levels were significantly increased in tumor samples with elevated P-S6 compared with tumor samples with decreased P-S6 (Figure 6d ). Taken together with our isogenic and breast cancer cell data, these findings indicate that the aberrant activation of mTORC1 in cancer promotes a lipogenic program through the activation of SREBP and its gene targets.
DISCUSSION
An important metabolic characteristic of cancer cells that distinguishes them from their cells of origin is their enhanced capacity to synthesize, de novo, the major macromolecules needed to make new cells, including proteins, nucleotides and lipids. 43 Although there has been much progress in defining the unique metabolic properties of cancer cells, how these properties are acquired over the course of oncogenic transformation is less well understood. In this study, we demonstrate that mTORC1 activation downstream of oncogenic PI3K and Ras signaling is a major mechanism by which cancer cells stimulate aberrantly elevated rates of de novo lipid synthesis. Furthermore, we show that the SREBP family of transcription factors, well-established promoters of lipid synthesis in physiological settings, such as the liver, 6 are the key downstream effectors of mTORC1 promoting oncogene-induced lipid synthesis.
SREBP has emerged as a major effector of mTORC1 signaling. Porstmann et al. 44 were the first to show that aberrant activation of an oncogene (Akt) could activate SREBP, and this was later found to be through downstream activation of mTORC1. 14 In a bioinformatics search for common cis-regulatory elements in the promoters of mTORC1-induced genes, we identified SREs, which are recognized by SREBP, to be most prevalent, demonstrating the importance of SREBP as a primary downstream transcriptional effector of mTORC1. 13 How mTORC1 activates SREBP is unknown, although multiple direct downstream targets of mTORC1 have been implicated. 12 These distinct mechanisms are likely to underlie the differential sensitivity of SREBP1/2 processing and lipid synthesis to rapamycin and TOR kinase inhibitors. It is now clear that the mTORC1/SREBP1c pathway represents a major route by which insulin signaling activates physiological lipid synthesis in the liver. 15, 16, 20, 22 Recent studies have also implicated an important role for the SREBPs in cancer cell viability. 37, [45] [46] [47] We find that activation of the mTORC1/SREBP pathway underlies the elevated lipid synthesis observed in cancer cells, providing a key link between oncogenic signaling and this metabolic process. Relative to SREBP1, SREBP2 appears to have a stronger effect on de novo lipogenesis and proliferation in the cell settings used in this study. It is not clear whether this is because of a specific function of SREBP2 that, unlike SREBP1, is embryonic lethal if knocked out in mice, 48 or whether it is because of the influence of SREBP2 on SREBP1 expression detected here and in previous studies, 13, 37, 38 resulting in a functional decrease in both isoforms upon SREBP2 knockdown.
Lipogenic enzymes transcriptionally activated by the SREBPs have emerged as potential therapeutic targets in cancer. Chemical inhibition or genetic knockdown of ATP citrate lyase (ACLY), 49, 50 FASN, 2 and SCD [51] [52] [53] have been found to reduce proliferation and survival in a variety of cancer cells and xenograft tumor models. 2, 50 Recent studies have suggested that proliferating cells need to coordinate protein synthesis with the synthesis of MUFAs, prevalent in membrane phospholipids, to prevent endoplasmic reticulum stress, 37, 54 suggesting a potential selective pressure for the coregulation of protein and lipid synthesis by mTORC1. SCD is required for the production of MUFAs and is, therefore, particularly important for the proliferation and survival of cancer cells. [51] [52] [53] Blocking the mevalonate pathway downstream of SREBP, which is responsible for isoprenoid and cholesterol production, has also been found to reduce cancer cell viability. 55, 56 Despite the apparent importance of de novo lipogenesis in some cancer settings, it is unclear what role lipid uptake plays and whether exogenous lipids become limiting for cancer cells in the tumor microenvironment. In our study, depletion of serum lipids had little effect on the sensitivity of breast cancer cells to PTEN mutation with undefined effect.
Oncogenic lipogenesis through mTORC1 and SREBP SJH Ricoult et al knockdown of SREBP isoforms. However, in the oncogeneexpressing MCF10a lines, a requirement for SREBP was only revealed under conditions of low serum, where oncogenic PI3K and K-Ras exert a proliferation advantage. Interestingly, cancer cells cultured in hypoxic conditions have been shown to be dependent on the uptake of exogenous lipids for sustained growth and survival, and this has been attributed to the oxygen dependence of SCD for its production of endogenous MUFAs. 54, 57 Consistent with our findings that SCD is essential for the mTORC1-and SREBP-dependent stimulation of de novo lipid synthesis downstream of oncogenes (Figure 2g ), Kamphorst et al. 57 have demonstrated that activated Akt stimulates the de novo production of MUFAs. In contrast, they found that oncogenic Ras actually decreases cellular MUFA content and enhances the percentage of MUFAs acquired through uptake of exogenous lipids. In addition to increasing lipid uptake, 57 we show in a distinct isogenic setting that oncogenic K-Ras can also enhance de novo lipid synthesis under conditions where exogenous lipids are not readily available. Interestingly, relative to cells expressing oncogenic PI3K, SCD was found to be less critical for Ras-stimulated lipogenesis in our assays, consistent with these previous findings. 57 It is important that we gain a better understanding of the balance between lipid synthesis and uptake in the tumor microenvironment and how distinct oncogenic lesions influence this in different cancers. It is interesting to note that a major physiological effect of systemic treatment with rapamycin is an increase in circulating lipids, 58, 59 likely resulting from the stimulation of lipolysis in adipose tissue. [60] [61] [62] Such an increase in the availability of exogenous lipids to growing tumors might overcome the suppressive effects of mTORC1 inhibition on de novo synthesis within the tumor. Our data here suggest that oncogenic activation of mTORC1 and its downstream induction of an SREBP-driven lipogenic program are key elements to the transforming capacity of PI3K and K-Ras signaling. Together with established downstream effectors of these pathways that promote cancer cell survival and proliferation, activation of the mTORC1/SREBP pathway serves to enhance cell-autonomous growth.
MATERIALS AND METHODS

Cell culture
All cell lines were obtained from ATCC (Manassas, VA, USA) and maintained in RPMI-1640 with 10% fetal bovine serum at 37°C and 5% CO 2 . Lipid-reduced fetal bovine serum was made by mixing with fumed silica (20 mg/ml; S5130, Sigma, St Louis, MO, USA) for 3 h. Pools of MCF10A cells stably expressing pBabe-Puro-vector, -PI3KCA H1047R (12524, Addgene, Cambridge, MA, USA) 63 or K-Ras G12V (9052, Addgene), via retroviral transduction, were selected and cultured in Dulbecco's modified Eagle's medium/F12 with 5% horse serum, epidermal growth factor (20 ng/ml), hydrocortisone (0.5 mg/ml), cholera toxin (100 ng/ml), insulin (10 μg/ml) and puromycin (1 μg/ml) at 37°C and 5% CO 2 . Rapamycin (553210, Calbiochem, San Diego, CA, USA), PP242 (4257, Tocris, Bristol, UK) and Torin1 (4247, R&D Systems, Minneapolis, MN, USA) were used to inhibit mTOR.
Plasmids and siRNAs
The pLKO mouse SREBP2 plasmid (Addgene 32018) was a gift from David Sabatini.
22 SREBP2 shRNAs from the RNAi consortium were used:
shSREBP2#1 (TRCN0000020665), shSREBP2#2 (TRCN0000020667), shSREBP2#3 (TRCN0000020666) and shSREBP2#4 (TRCN0000020668).
All siRNA experiments used ON-TARGET-plus SMARTpool siRNAs (30 nM; Dharmacon/GE, Lafayette, CO, USA) transfected using Lipofectamine RNAiMAX (Invitrogen, Grand Island, NY, USA) according to the manufacturer's instructions for reverse transfection. For Raptor and Rictor knockdowns, siRNAs were transfected on two consecutive days to achieve efficient knockdown. Each siRNA and shRNA targeting SREBP2 recognized a unique sequence in SREBF2, with at least five mismatches toward any sequence in SREBF1, and vice versa.
Immunoblotting
Cells were lysed in NP-40 buffer (40 mM HEPES, pH 7.4; 400 mM NaCl; 1 mM EDTA, pH 8.0; 1% NP-40 (CA-630, Sigma); 5% glycerol; 10 mM pyrophosphate; 10 mM β-glycerophosphate; 50 mM NaF; 0.5 mM orthovanadate) containing Protease Inhibitor Cocktail (Sigma) and 1 mM dithiothreitol. Nuclear isolation was performed with a Nuclear Extract Kit (40010, Active Motif, Carlsbad, CA, USA), with 10 μg/ml ALLN (208719, Millipore, Bedford, MA, USA) treatment 20 min before isolation, and ALLN added to the hypotonic and lysis buffers. The nuclear fraction was washed with hypotonic buffer before lysis. Antibodies used for immunoblots recognized SREBP1 (sc-8984, Santa Cruz, Santa Cruz, CA, USA), SREBP2 precursor and processed C-terminus Cell proliferation, size and death Cell number and size were measured in solution, following trypsinization, using a Z2 Coulter Counter (Beckman Coulter). Medium was replaced every 24 h. For cell death, adherent and nonadherent cells were combined, washed in phosphate-buffered saline and resuspended in Annexin buffer (10 mM HEPES; 140 mM NaCl; 2.5 mM CaCl 2 , pH 7.4) before incubation with Annexin-V/FITC conjugate (A13199, Invitrogen) for 15 min. Cells for each sample were resuspended in Annexin buffer containing propidium iodide (P4170, Sigma) before analyzing by flow cytometry (FACS Calibur, BD). Percent cell death was calculated by dividing the sum of the cells positive for propidium iodide, Annexin-V or both by the total number of cells.
Analysis of TCGA data
Reverse-phase protein array and gene expression data were downloaded from cBioPortal. [40] [41] [42] Samples with P-S6-S240 levels 41 s.d. above average were classified as 'High Phospho-S6', whereas those 41 s.d. below average were classified as 'Low Phospho-S6'.
Breast cancer patient lysate arrays Breast cancer patient lysate arrays (PMA2-001-L, Protein Biotechnologies, Ramona, CA, USA) were blotted following the manufacturer's instructions. Colloidal gold staining (170-6527, Bio-Rad, Waltham, MA, USA) was used to determine total protein content. Signal from 40 of 55 samples was detectable for FASN and 37 of 55 samples for SCD. Dot intensity was measured with ImageJ. 64 'High Phospho-S6' samples had a fold change in P-S6 levels between the tumor and normal tissues greater than log 2 (0.5), whereas 'Low Phospho-S6' were those lower than log 2 (−0.5).
Statistical analysis
All data were analyzed with GraphPad Prism (La Jolla, CA, USA). P-values were calculated by an unpaired two-tailed Student's t-test, where appropriate.
